| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00078-0628-51 | 00078-0628 | Everolimus | Afinitor | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Aug 29, 2012 | In Use | |
| 55150-0383-01 | 55150-0383 | Pemetrexed | Pemetrexed | 1000.0 mg/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
| 76420-0375-20 | 76420-0375 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 19, 2025 | In Use | |
| 54569-4648-02 | 54569-4648 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 4.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Sep 7, 2000 | In Use | |
| 24979-0715-04 | 24979-0715 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Dec 1, 2022 | In Use | |
| 63187-0379-10 | 63187-0379 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 1, 2016 | In Use | |
| 71205-0665-21 | 71205-0665 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 26, 2022 | In Use | |
| 71335-1772-02 | 71335-1772 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec 29, 2021 | In Use | |
| 60687-0252-67 | 60687-0252 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 5, 2019 | In Use | |
| 52959-0547-21 | 52959-0547 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 28, 1983 | In Use | |
| 68462-0106-33 | 68462-0106 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
| 16729-0108-11 | 16729-0108 | Mitomycin | Mitomycin | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jun 10, 2009 | In Use | |
| 63629-4413-06 | 63629-4413 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Mar 7, 2011 | In Use | ||
| 50090-7369-00 | 50090-7369 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 18, 2024 | In Use | |
| 62175-0243-19 | 62175-0243 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 10, 2016 | In Use | |
| 70518-3539-02 | 70518-3539 | PREDNISONE | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 6, 2025 | In Use | |
| 68071-1904-04 | 68071-1904 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 22, 2017 | In Use | |
| 14789-0600-10 | 14789-0600 | Arsenic Trioxide | Arsenic Trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Nov 19, 2018 | In Use | |
| 00121-2106-02 | 00121-2106 | Leuprolide acetate | Leuprolide acetate | 5.0 mg/1ml | Hormonal Therapy | GnRH Agonist | Subcutaneous | Feb 1, 2025 | In Use | ||
| 40051-0606-51 | 40051-0606 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
| 85766-0001-90 | 85766-0001 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 19, 2025 | In Use | |
| 62135-0772-35 | 62135-0772 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug 29, 2023 | In Use | |
| 68071-2209-01 | 68071-2209 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 7, 2020 | In Use | |
| 71288-0127-15 | 71288-0127 | Topotecan Hydrochloride | Topotecan | 4.0 mg/15mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sep 2, 2019 | In Use | |
| 42043-0390-02 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 12, 2016 | In Use |
Found 12250 results — Export these results
Home